Global BCMA-targeted CAR-T Cell Therapy Market Strategic Research Report

Scope of the Report

The global BCMA-targeted CAR-T Cell Therapy market size is predicted to grow from US$ 1,764 million in 2025 to US$ 8,619 million in 2032; it is expected to grow at a CAGR of 25.9% from 2026 to 2032.

Chimeric antigen receptor (CAR) T-cell therapy is a type of cancer immunotherapy treatment that uses immune cells called T cells that are genetically altered in a lab to enable them in locating in destroying cancer cells more effectively. Currently available CAR-T cell therapy products are divided into CD19 targets and BCMA targets. BCMA stands for B - cell maturation antigen. It is a protein that is found on the surface of plasma cells, which are abnormal cells that multiply uncontrollably in multiple myeloma, a type of blood cancer. By targeting BCMA, the CAR - T cell therapy aims to specifically attack the cancer - causing plasma cells.

Major players: The BCMA-targeted CAR-T cell therapy market presents a highly concentrated duopoly. In 2024, the global market CR2 index exceeded 98%. The main products are Carvykti (Cedacion) jointly developed by Legend Biotech and Johnson & Johnson and Abecma of Bristol-Myers Squibb. Among them, Carvykti continues to expand its market leadership with significant clinical advantages, and its global sales in 2024 increased by 93% year-on-year. In contrast, Abecma's sales in the current period decreased by about 14% year-on-year due to intensified market competition and product iteration pressure.

Market Trends: The BCMA CAR - T cell therapy market is in a phase of rapid growth. The reasons for this growth are two - fold. Firstly, there is a large population of patients with multiple myeloma, and there are many unmet medical needs. Secondly, this therapy has demonstrated good efficacy and has been recognized by the market. With the maturation of technology and market promotion, it is expected that the market will maintain a high growth rate in the coming years.

Expansion of Indications: Currently, BCMA CAR - T cell therapy is mainly used for the treatment of relapsed or refractory multiple myeloma. With the deepening of research, its indications are expected to be broadened. Pre - clinical and clinical trials are exploring its application in other hematological malignancies, such as certain types of leukemia and lymphoma. If successful, this will greatly expand the market size, bring hope to more patients, and inject new impetus into the growth of the therapy market.

Changing Competitive Landscape：The market competition is becoming increasingly fierce. In addition to the already - launched products such as Ciltacabtagene Autoleucel (Carvykti) and Idecabtagene Vicleucel (Abecma), many pharmaceutical companies are actively deploying and researching BCMA CAR - T products. New entrants may change the existing competitive landscape with innovative technologies or better cost control.

High - Cost Constraints: The research, development, and production processes of BCMA CAR - T cell therapy are complex, involving multiple high - cost links such as cell collection, gene editing, and cell culture, resulting in high product prices. This makes it difficult for many patients to afford, limiting the accessibility of the therapy and, to a certain extent, hindering the rapid expansion of the market. How to reduce costs so that more patients can benefit is an important challenge faced by the entire industry.

Safety Risks：Although this therapy has achieved remarkable results in clinical applications, there are still certain safety risks, such as cytokine release syndrome (CRS) and neurotoxicity. These adverse reactions may have a serious impact on the health of patients and even endanger their lives.

This report presents a comprehensive overview of the global BCMA-targeted CAR-T Cell Therapy market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Abecma
• Carvykti
• Others

Segment by Application

• Hospital
• Oncology Clinic

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global BCMA-targeted CAR-T Cell Therapy market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Hospital, Oncology Clinic evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact